{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:41:56Z","timestamp":1792276916095,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cmi.2026.10.012","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:39:10Z","timestamp":1792276750000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of trimethoprim-sulfamethoxazole dosing strategies for Pneumocystis jirovecii pneumonia: a target trial emulation"],"prefix":"10.1016","author":[{"given":"Revanth S.","family":"Yendamuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Rust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle D.","family":"Brizendine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Yetmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.10.012_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrmicro1621","article-title":"Current insights into the biology and pathogenesis of Pneumocystis pneumonia","volume":"5","author":"Thomas","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2026.10.012_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis Pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.10.012_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.10.012_bib4","unstructured":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Rockville (MD): US Department of Health and Human Services, 2026. Available at: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-oi\/guidelines-adult-adolescent-oi.pdf. Accessed 7 April 2026."},{"key":"10.1016\/j.cmi.2026.10.012_bib5","first-page":"47","article-title":"Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole","author":"Hughes","year":"1975","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.cmi.2026.10.012_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-3476(78)80028-6","article-title":"Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia","volume":"92","author":"Hughes","year":"1978","journal-title":"J Pediatr"},{"key":"10.1016\/j.cmi.2026.10.012_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s15010-015-0851-1","article-title":"Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim\u2013sulfamethoxazole: lessons from an observational cohort study","volume":"44","author":"Creemers-Schild","year":"2016","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2026.10.012_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jmii.2017.07.007","article-title":"Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study","volume":"51","author":"Nakashima","year":"2018","journal-title":"Journal of Microbiology, Immunology and Infection"},{"key":"10.1016\/j.cmi.2026.10.012_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.chest.2023.08.009","article-title":"Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV","volume":"165","author":"Nagai","year":"2024","journal-title":"CHEST"},{"key":"10.1016\/j.cmi.2026.10.012_bib10","doi-asserted-by":"crossref","first-page":"e1252","DOI":"10.1093\/cid\/ciac386","article-title":"Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies","volume":"76","author":"Hammarstr\u00f6m","year":"2023","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.cmi.2026.10.012_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa112","article-title":"Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis","volume":"7","author":"Butler-Laporte","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.cmi.2026.10.012_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13737","article-title":"The effectiveness and safety of low dose trimethoprim\u2010sulfamethoxazole for the treatment of pneumocystis pneumonia: A systematic review and meta\u2010analysis","volume":"23","author":"Tritle","year":"2021","journal-title":"Transplant Infectious Dis"},{"key":"10.1016\/j.cmi.2026.10.012_bib13","unstructured":"Trimethoprim\/Sulfamethoxazole (Septra) Package Insert | DAIDS Regulatory Support Center (RSC). Available at: https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/septra-trimethoprim-and-sulfamethoxazole-tablets-package-insert. Accessed 11 September 2026."},{"key":"10.1016\/j.cmi.2026.10.012_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13587","article-title":"Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Fishman","year":"2019","journal-title":"Clinical Transplantation"},{"key":"10.1016\/j.cmi.2026.10.012_bib15","unstructured":"National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. 2026. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections\/whats-new. Accessed 11 September 2026."},{"key":"10.1016\/j.cmi.2026.10.012_bib16","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C\u2013Based Equations to Estimate GFR without Race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.10.012_bib17","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.cmi.2026.10.012_bib18","doi-asserted-by":"crossref","first-page":"1242.e11","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2026.10.012_bib19","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS, France","volume":"20","author":"Roux","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2026.10.012_bib20","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1128\/JCM.02072-15","article-title":"Impact of HIV Infection Status on Interpretation of Quantitative PCR for Detection of Pneumocystis jirovecii","volume":"53","author":"Louis","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2026.10.012_bib21","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1128\/JCM.03174-15","article-title":"Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients","volume":"54","author":"Fauchier","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2026.10.012_bib22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.cmi.2026.10.012_bib23","unstructured":"Lee TC. Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia. clinicaltrials.gov, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04851015. Accessed 10 September 2026."}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26005859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26005859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:39:13Z","timestamp":1792276753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26005859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"alternative-id":["S1198743X26005859"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.10.012","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of trimethoprim-sulfamethoxazole dosing strategies for Pneumocystis jirovecii pneumonia: a target trial emulation","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}